DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Endometrial Mucinous Adenocarcinoma — screening already-approved drugs against its 7-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEndometrial Mucinous Adenocarcinoma maps to a 7-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for endometrial mucinous adenocarcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
KRas proto-oncogene, GTPase (KRAS) — KRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gnpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7VVB · 1.7 Å · ligand PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER (GNP). Experimental structure, not a prediction.
What the evidence adds up to
Of 1640 women with endometrial carcinoma seen at one centre between 1993 and 2013, only 11 (0.67%) had pure mucinous type. Mean age was 55 years. Ten of the 11 (90.9%) were stage I; one was stage IIIC1. Lymph node metastasis was found in one of eight patients who had lymphadenectomy (12.5%). Four patients received adjuvant pelvic radiotherapy. Median follow-up was 50 months. One recurrence occurred, in the stage IIIC1 patient, at 30 months after primary surgery, in the upper abdomen. The authors concluded that stage I disease can be managed with surgery alone and that the prognosis is good.
A separate case report describes a patient who developed mucinous endometrial carcinoma 18 years after bilateral ovariectomy for ovarian endometrioid adenocarcinoma. The report notes that oestrogen stimulation is often postulated as a factor in such endometrial cancers, but the long interval after ovarian removal complicates that explanation.
No abstract in this set reports any drug treatment or drug response data for mucinous endometrial adenocarcinoma. The 2016 abstract on CA 19-9 as a predictor of advanced disease and nodal involvement is cut off and provides no results. The evidence base remains limited to small surgical case series and single case reports. What is missing is any prospective trial, any biomarker-validated stratification, any drug-repurposing data, and any funding for a disease this rare.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Northern Clinics of Istanbul · 2019 · 6 citations · open access
Mucınous Endometrial Cancer: Clinical Study of Eleven Cases
AbstractOBJECTIVE: In this study, we analyzed surgico-pathologic factors of mucinous type endometrial carcinoma and examined its frequency of recurrence. METHODS: In this study, eleven cases, definitely diagnosed as pure mucinous type endometrium carcinoma between January 1993 and May 2013, were reviewed. RESULTS: Of 1640 women with endometrium carcinoma, 11 (0.67%) of them had a mucinous cell type. Mean age of the study group was 55 years. According to the FIGO 2009, 10 (90.9%) cases were evaluated as stage I and 1 (9.1%) as stage IIIC1. The presence of lymph node metastasis was noticed in only one (12.5%) of eight patients who underwent lymphadenectomy. In this case, metastasis was detected in the pelvic lymph node. Four patients underwent adjuvant therapy as pelvic radiotherapy. Median follow-up time was 50 months (range, 5-84). Recurrence was observed in one (9.1%) patient with stage IIIC1 endometrial cancer in 30 months after primary surgery. The site of recurrence was only in the upper abdominal region. CONCLUSION: Based on our study, mucinous endometrial carcinoma has good prognostic factors, and long term survival can be achieved surgically alone in patients with stage I.
Mucinous Endometrial Carcinoma in a Patient with Previous Ovarian Endometrioid Adenocarcinoma Presenting Some 18 Years after Initial Bilateral Ovariectomy: A Case Report
AbstractThe association of endometrioid carcinoma of the ovary and primary carcinoma of the endometrium is well recognised. These tumours are often synchronous in occurrence. Oestrogen stimulation is often postulated as a significant factor in the development of the endometrial carcinoma in such cases. We describe the case of a patient who developed a mucinous endometrial carcinoma 18 years after initial bilateral ovariectomy. The aetiology and pathogenesis of the uterine tumour is discussed.
West Indian Medical Journal · 2016 · 0 citations · open access
Ca 19-9 Could Predict both Advanced Disease and Nodal Involvement in Primary Mucinous Endometrial Cancers
AbstractObjective: Mucinous endometrial carcinoma is a rare disease. A study to evaluate and find predictive factors of mucinous endometrial carcinoma for advanced disease and nodal involvement was performed. Methods: Patients who were operated at the Gynecologic Oncology Department of Zekai Tahir Burak Women’s Health, Education and Research Hospital between January 2006 and
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
